P08581 (MET_HUMAN) Homo sapiens (Human)

Hepatocyte growth factor receptor UniProtKBInterProSTRINGInteractive Modelling

1390 aa; Sequence (Fasta) ; (Isoform 2; Isoform 3)

Available Structures

118 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
107_A07 Fab in complex with fragment of the Met receptor Heteromer
25-740
100NAG;
Cryo-EM structure of 2:2 c-MET/HGF holo-complex Heteromer
P14210;
26-740
100.0SGN;
Cryo-EM map of the c-MET II/HGF I/HGF II (K4 and SPH) sub-complex Heteromer
P14210;
26-738
100.0SGN;
Cryo-EM structure of the c-MET II/HGF I complex bound with HGF II in a rigid conformation Heteromer
P14210;
26-738
100.0SGN;
MET receptor in complex with InlB internalin domain and DARPin A3A Heteromer
40-740
100.0
Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes inva… Heteromer
P0DQD2;
42-741
99.84
Cryo-EM structure of 1:1 c-MET I/HGF I complex after focused 3D refinement of holo-complex Heteromer
P14210;
26-654
100.0SGN;
Structure of the human receptor tyrosine kinase Met in complex with the Listeria monocytogenes inva… Heteromer
P0DQD2;
42-658
99.82
Crystal structure of Onartuzumab Fab in complex with MET and HGF-beta Heteromer
P14210;
39-564
100.0NAG;
Zymogen HGF-beta/MET with Zymogen Activator Peptide ZAP2.3 Heteromer
P14210;
39-564
100.0
Zymogen HGF-beta/MET with Zymogen Activator Peptide ZAP.14 Heteromer
P14210;
40-564
100.0NAG;1PE;
Crystal structure of anti-MET Fab arm of amivantamab in complex with human MET Heteromer
40-564
100.0NAG;NAG;NAG;FMT;
The Crystal Structure of HGF beta-chain in Complex with the Sema Domain of the Met Receptor. Heteromer
P14210;
40-564
100.0
Cryo-EM structure of 2:2 c-MET/NK1 complex Heteromer
P14210;
33-557
100.0
Crystal structure of Sema domain of the Met receptor in complex with FAB Heteromer
41-517
100.0
Crystal structure of c-Cbl-TKB domain complexed with its binding motif in c-Met Heteromer
P22681;
998-1005
100
DIMER FORMATION THROUGH DOMAIN SWAPPING IN THE CRYSTAL STRUCTURE OF THE GRB2-SH2 AC-PYVNV COMPLEX Heteromer
P62993;
1355-1359
80.0
Crystal structure of the c-Met kinase domain in complex with a pyrazolone inhibitorhomo-2-mer1050-1350
100.075H;
Structure of c-Met with pyrimidone inhibitor 50homo-2-mer1054-1351
100.0MT4;
Structure of c-Met with pyrimidone inhibitor 7homo-2-mer1054-1351
100.0MT3;
CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN C…homo-2-mer1050-1346
1005B4;
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibodymonomer1029-1360
100.084M;GOL;CL;
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibodymonomer1029-1360
100.084S;CL;
MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibodymonomer1029-1360
100.084P;CL;
Crystal structure of human c-Met kinase domain with its inhibitormonomer1024-1352
100.0DF6;CL;
Structure of MET receptor tyrosine kinase in complex with inhibitor SGX-523monomer1050-1360
99.66CL;SX8;
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met in c…monomer1050-1360
99.0KSA;
CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-METmonomer1050-1360
99.65
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-MET in c…monomer1050-1360
99.66CKK;
Structure of MET receptor tyrosine kinase in complex with ATPmonomer1051-1360
99.03MG;CL;ATP;
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in c…monomer1051-1360
99.65320;
c-Met Kinase in Complex with NVP-BVU972monomer1052-1360
99.313QT;CL;
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-met in c…monomer1052-1360
99.66319;
Structure of Mutant(Y1248L) MET receptor tyrosine kinase in complex with inhibitor SGX-523monomer1050-1356
99.64CL;SX8;
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in c…monomer1054-1360
99.661FN;
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in c…monomer1054-1360
99.66L8V;
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor C-MET in c…monomer1055-1360
99.64353;
Crystal structure of mutant cMET D1228N kinase domain in complex with inhibitor compound 13monomer1047-1348
99.64GOL;A1ATS;
Crystal structure of c-Met in complex with LY2801653monomer1045-1346
100.0L1X;
Structure of the apo MET receptor kinase in the dually-phosphorylated, activated statemonomer1048-1348
100.0
Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-8033 analogmonomer1048-1348
100.01JC;
Crystal structure of c-Met in complex with pyrazolone inhibitor 26monomer1051-1351
100.003X;
Crystal structure of c-Met in complex with pyrazolone inhibitor 58amonomer1051-1351
100.0044;
Structural Characterization of autoinhibited c-Met kinasemonomer1046-1346
100
Structure of dually phosphorylated c-MET receptor kinase in complex with an MK-2461 analogmonomer1048-1348
100.0M61;
Structure of dually-phosphorylated MET receptor kinase in complex with an MK-2461 analog with speci…monomer1050-1348
100.0Q6W;
Crystal structure of c-Met mutant Y1230H in complex with compound 14monomer1057-1355
99.65CL;62E;
Human c-Met Kinase in complex with quinoxaline inhibitormonomer1052-1349
100.0IHX;GBL;
Crystal structure of the catalytic domain of c-Met kinase in complex with ARQ 197monomer1049-1346
100M97;
c-MET Y1234E,Y1235E mutant in complex with Tepotinibmonomer1052-1349
100.03E8;
human c-MET kinase domain complexed with 6-benzyloxyquinoline inhibitormonomer1063-1360
99.65CL;IPA;DFQ;
Crystal structure of cMET kinase domain bound by TPX-0022monomer1048-1345
100IYC;
Crystal structure of c-Met in complex with AMG 337monomer1052-1348
100.05T1;
Crystal structure of D1228V c-MET bound by compound 10monomer1051-1346
99.65W3W;
Crystal structure of CMET in complex with novel inhibitormonomer1052-1346
100.0DWF;
Crystal structure of c-Met kinase domain in complex with LXM108monomer1052-1346
100.066L;
Crystal structure of D1228V cMET bound by foretinibmonomer1052-1346
99.6588Z;
Crystal structure of c-Met in complex with (R)-5-(8-fluoro-3-(1-fluoro-1-(3-methoxyquinolin-6-yl)et…monomer1051-1345
100.046G;
Crystal structure of c-Met in complex with (S)-5-(8-fluoro-3-(1-(3-(2-methoxyethoxy)quinolin-6-yl)e…monomer1052-1346
100.044X;
Crystal structure of c-Met in complex with triazolopyridazine inhibitor 2monomer1052-1346
100.00JJ;
Crystal structure of c-Met with triazolopyridazine inhibitor 13monomer1052-1346
100.0B2D;
Crystal structure of D1228V c-MET bound by compound 1.monomer1052-1346
99.64GOL;MDI;
x-ray structure of c-Met with inhibitor.monomer1057-1351
100.0AM7;
X-ray Structure of c-Met kinase in complex with inhibitor (S)-3-(1-(1H-pyrrolo(2,3-b)pyridin-3-yl)e…monomer1052-1345
100.05TF;
Crystal structure of CMET in complex with a novel inhibitormonomer1053-1346
100.05IE;
CRYSTAL STRUCTURE OF CMET WT with compound 3monomer1063-1356
99.5963B;
Crystal structure of D1228V c-MET bound by compound 15monomer1053-1346
99.66W3R;
Crystal structure of C-MET kinase domain in complex with 4-((6-(4- fluorophenyl)-(1,2,4)triazolo(4,…monomer1052-1345
100.0F47;
X-ray Structure of PF-04217903 bound to the kinase domain of c-Metmonomer1052-1345
100.0KRW;
Crystal structure of CMET in complex with a novel inhibitormonomer1053-1346
100.05I9;
CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD.monomer1063-1356
99.5863K;
Crystal structure of c-Met in complex with triazolopyridinone inhibitor 3monomer1053-1346
100.00JK;
X-ray Structure of PF-02341066 bound to the kinase domain of c-Metmonomer1052-1345
100.0VGH;
Crystal structure of c-Met in complex with triazolopyridinone inhibitor 24monomer1053-1346
100.00JL;
X-ray Structure of c-Met kinase in complex with inhibitor (S)-6-(1-(6- (1-methyl-1H-pyrazol-4-yl)-(…monomer1052-1345
100.0W9Z;
Crystal structure of c-Met in complex with naphthyridinone inhibitor 5monomer1053-1345
100.05SZ;
Crystal structure of C-MET kinase domain in complex with 4-(3-((1H- pyrrolo(2,3-b)pyridin-3-yl)meth…monomer1052-1344
100.04K0;
X-ray Structure of c-Met with triazolopyridazine Inhibitor.monomer1054-1346
100.0L5G;
Structure of the kinase domain of c-Met bound to XL880 (GSK1363089)monomer1053-1345
100.088Z;
Crystal structure of c-Met-M1250T in complex with SAR125844.monomer1064-1356
99.1963K;
Crystal structure of c-MET bound by compound S1monomer1055-1346
100.0SVT;DMS;SO4;
Crystal structure of c-MET bound by compound 6monomer1055-1346
100.0SWN;
X-ray structure of c-Met with triazolopyridazine inhibitor.monomer1055-1346
100.0LKG;
Crystal structure of c-MET bound by compound 7monomer1055-1346
100.0SWK;
Human c-Met Kinase in complex with azaindole inhibitormonomer1055-1346
100.0ZZY;GBL;
Crystal structure of c-Met L1195V in complex with SAR125844monomer1065-1356
99.1163K;
Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitorsmonomer1055-1345
100.03E8;GBL;
Crystal structure of CMET in complex with novel inhibitormonomer1055-1345
100.05QQ;
Crystal structure of c-MET bound by compound 1monomer1055-1344
100.0SV5;SO4;
Crystal structure of c-MET bound by compound 5monomer1055-1344
100.0DMS;SV8;
Crystal structure of c-MET bound by compound 8monomer1055-1344
100.0SW8;
Crystal structure of c-MET bound by compound 9monomer1055-1344
100.0SW5;
CRYSTAL STRUCTURE OF c-MET IN COMPLEX WITH NOVEL INHIBITORmonomer1057-1345
100.06TD;
Crystal structure of D1228V c-MET bound by compound 29monomer1059-1346
99.65GOL;EDO;FMT;W49;
Crystal structure of c-MET bound by compound 3monomer1057-1344
100.0SWB;
Crystal structure of wild-type c-MET bound by compound 2monomer1058-1345
100.0W40;
Crystal structure of C-MET kinase domain in complex with N'-((3Z)-4- chloro-7-methyl-2-oxo-1,2-dihy…monomer1059-1345
1006XP;
X-ray Structure of PHA-00665752 bound to the kinase domain of c-Metmonomer1059-1345
100PFY;
X-ray Structure of c-Met kinase in complex with inhibitor 6-((6-(4- fluorophenyl)-(1,2,4)triazolo(4…monomer1059-1345
100.06XE;
Crystal structure of D1228V c-MET bound by compound 16monomer1061-1346
99.6510×IOD;W3N;
Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitormonomer1062-1346
100.03EH;7PE;
Crystal structure of D1228V c-MET bound by compound 2monomer1060-1344
99.59W40;
Crystal structure of cMET kinase domain bound by D6808monomer1060-1344
100KGL;
Crystal structure of cMET kinase domain bound by compound 9Ymonomer1061-1344
100.0I94;
Crystal structure of wild-type cMET bound by foretinibmonomer1062-1345
100.0CL;88Z;
Crystal structure of D1228V cMET bound by BMS-777607monomer1062-1344
99.63353;GOL;
Crystal structure of cMET kinase domain bound by compound 9Imonomer1063-1345
100.0I90;
Crystal structure of c-MET bound by compound 2monomer1062-1344
100.0SVK;CL;SO4;
Crystal structure of cMET in complex with novel inhibitormonomer1064-1344
100.00J8;
C-Met in complex with OSI ligandmonomer1064-1344
100.01RU;GBL;
Crystal structure of CMET in complex with novel inhibitormonomer1064-1344
100.00J3;
c-MET Y1235D mutant in complex with Tepotinibmonomer1066-1345
99.623E8;
X-ray structure of SU11274 bound to c-Metmonomer1067-1346
100.0AM8;
c-MET F1200I mutant in complex with Tepotinibmonomer1067-1346
99.623E8;EDO;CL;
Crystal structure of wild-type cMET bound by savolitinibmonomer1068-1346
100.0V0L;
Crystal structure of c-MET bound by compound 4monomer1067-1344
100.0EDO;SVH;
Crystal structure of wild-type c-MET bound by compound 7.monomer1073-1345
100.0SO4;MDI;
Solution structure of the PSI domain from the Met receptormonomer519-562
100

3 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
6gcu.1.Amonomer0.7940-740
100.00
7mo7.1.Dmonomer0.7626-740
100.00
6jrx.1.Amonomer0.681075-1344
37.97

6 SWISS-MODEL models built on isoform sequence

IsoformTemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 26gcu.1.Amonomer0.7940-740
100.00
Isoform 27mo7.1.Dmonomer0.7626-740
100.00
Isoform 22uzy.1.Bmonomer0.7342-741
99.72
Isoform 28a2d.1.Amonomer0.681093-1364
37.69
Isoform 36gcu.1.Amonomer0.8040-740
100.00
Isoform 37mo7.1.Bmonomer0.7626-738
98.95